WaveBreak is a biopharmaceutical company focused on transforming drug discovery for neurodegenerative diseases, targeting the fleeting protein intermediates central to many disease pathways that are beyond the reach of conventional drug discovery approaches. WaveBreak has built a unique drug discovery platform to target the transient protein intermediates—the oligomers—in these disease pathways, to interrupt the molecular mechanisms that are the source of oligomer generation with small-molecule therapeutics. WaveBreak is focusing this platform first on some of the greatest unmet medical needs of our time: Parkinson’s disease, Lewy body dementia, Alzheimer’s disease, and ALS.
Company Details
- Employees
- 13
- Founded
- -
- Address
- Boston, Massachusetts, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- wrentherapeutics.com
- HQ
- Boston, Massachusetts
Wavebreak Questions
Wavebreak's website is wrentherapeutics.com
Wavebreak's LinkedIn profile is https://www.linkedin.com/company/wavebreak-therapeutics
Wavebreak has
13 employees.
View email and phone details for 13
employees at Wavebreak.
Wavebreak's industry is
Biotechnology Research
Wavebreak's top competitors are
Transition Bio, Inc.,
Pangea Bio,
Mosaic Tx,
Nereid Therapeutics,
Ride Therapeutics,
Quotient Therapeutics,
1base Pharmaceuticals,
Rectify Pharma,
Scorpion Therapeutics,
Apollo Therapeutics.
Wavebreak's categories are Biotechnology Research
Wavebreak's founding year is 2016
